Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors – Treatment or hypertension related? An observational cohort study
| Autor: | Anne-Katrin Fietz, Tatjana Tissen-Diabaté, Reinhard Meister, Corinna Weber-Schoendorfer, Angela Kayser, Christof Schaefer, Maria Hoeltzenbein, Sandra Zinke |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent Angiotensin-Converting Enzyme Inhibitors 030204 cardiovascular system & hematology Abortion Cohort Studies Young Adult 03 medical and health sciences 0302 clinical medicine Pre-Eclampsia Ramipril Pregnancy Germany Internal Medicine Humans Medicine Maternal hypertension Prospective Studies cardiovascular diseases 030212 general & internal medicine Methyldopa biology business.industry Obstetrics Hazard ratio Pregnancy Outcome Obstetrics and Gynecology Angiotensin-converting enzyme Odds ratio medicine.disease Abortion Spontaneous Pregnancy Trimester First biology.protein Female business medicine.drug Cohort study |
| Zdroj: | Pregnancy Hypertension. 13:65-71 |
| ISSN: | 2210-7789 |
| DOI: | 10.1016/j.preghy.2018.04.022 |
| Popis: | Objectives To analyze the risk of spontaneous abortions and major birth defects in pregnancies of women treated with angiotensin converting enzyme inhibitors (ACEIs) during the first trimester. Study design Observational cohort study of prospectively ascertained pregnancies from the German Embryotox pharmacovigilance institute. Pregnancy outcomes after maternal exposure to ACEIs during the first trimester were compared with pregnancies without antihypertensive treatment. In a sensitivity analysis, ACEI exposed hypertensive women were compared with hypertensive women on methyldopa. Results The risk of spontaneous abortion among 329 ACEI exposed women was not increased compared to 654 women without antihypertensive treatment (adjusted hazard ratio 1.20, 95% confidence interval (CI) 0.74–1.92), whereas the risk for major birth defects (14/255; 5.5% vs. 19/567; 3.4%) was significantly increased (adjusted odds ratio 2.41, 95% CI 1.07–5.43). In contrast, birth defect rates were not significantly different between hypertensive women on ACEIs and hypertensive women on methyldopa. In addition, we did not observe a distinct pattern of birth defects among retrospectively ascertained pregnancies after ACEI exposure during the first trimester. Conclusions Women with hypertension treated with ACEIs in early pregnancy are at higher risk for major birth defects, which may be explained by other factors associated with maternal hypertension. Women (inadvertently) exposed during early pregnancy may be reassured and treatment switched to antihypertensive drugs recommended for pregnancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect